SEC ownership of Larimar Therapeutics, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001374690.

Comparable stake leader

James E. Flynn

Disclosed value leader

James E. Flynn

Comparable rows

50/50

Latest evidence

30 Jun 2026

Top shareholders Insider holders Latest transactions
Public ticker
LRMR on Nasdaq
Parsed ownership sources
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
James E. Flynn
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
James E. Flynn
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001374690
Issuer location
Bala Cynwyd, PA

Ownership snapshot

Top shareholders of Larimar Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
James E. Flynn
Disclosed value leader
James E. Flynn
Comparable rows
50/50
Latest evidence
30 Jun 2026
3/4/5 13D/G 13F Lead comparable stake: 34% 13D/G row: James E. Flynn Showing 1-8 of 50 holder rows.

Quick read

James E. Flynn leads the comparable SEC ownership view at 34%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens James E. Flynn's linked filing trail.
Comparable ownership Top 5
James E. Flynn 34%
Blue Owl Capital Holdings LP 10%
BlackRock, Inc. 4.8%
Opaleye Management Inc. 4.8%
GOLDMAN SACHS GROUP INC 4.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
James E. Flynn
3/4/5 13D/G
Director, * Director by Deputization, 10%+ Owner · Deerfield Management Company, L.P.
3/4/5 13D/G
34%
from 13D/G
$178,034,870
35,662,124 shares
mixed-class rows
 +$25,000,000 19 May 2026
Blue Owl Capital Holdings LP
13D/G 13F
Company
13D/G 13F
10%
$54,234,435
10,739,492 shares
 +$11,487,886 31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
4.8%
from 13D/G
$17,318,006
5,678,035 shares
 — 30 Jun 2026
Opaleye Management Inc.
13D/G
13D/G
4.8%
$15,412,500
4,110,000 shares
 +$590,966 29 Aug 2025
GOLDMAN SACHS GROUP INC
13D/G 13F
THE GOLDMAN SACHS GROUP, INC. · Company
13D/G 13F
4.1%
$6,058,491
2,600,211 shares
 $0 31 Mar 2025
MILLENNIUM MANAGEMENT LLC
13D/G 13F
Company
13D/G 13F
3.5%
$16,313,751
3,625,278 shares
 -$6,036,988 31 Mar 2026
DEERFIELD MANAGEMENT COMPANY, L.P.
13F 3/4/5
Company · Director, * Director by Deputization, 10%+ Owner
13F 3/4/5
33%
$108,601,271
35,606,974 shares
 — 30 Jun 2026
Defilade Capital Management, L.P.
13F
Company
13F
3.4%
$11,193,912
3,670,135 shares
 — 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$25,716,890.

Buys
$25,716,890
Insiders: 4
Sells
$0
Insiders: 0
Net
+$25,716,890
Shares: +5,160,000
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 5,160,000 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 50,000 0 $166,890 $0 +$166,890
3-6 0 0 $0 $0 $0
6-9 5,110,000 0 $25,550,000 $0 +$25,550,000
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-14 of 14 reporting-owner rows connected to Larimar Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
14
Largest Forms 3/4/5 holder
James E. Flynn
Net 12M change
+$25,716,890
Latest report
06 Jul 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
James E. Flynn Director, * Director by Deputization, 10%+ Owner $178,034,870 +$25,000,000 +16% Filing P/S 19 May 2026
DEERFIELD PARTNERS, L.P. Director, Dir. by Deputization/10% Group, 10%+ Owner $10,367,497 Mixed 16 Sep 2022
Thomas Edward Hamilton Director $2,872,122 +$666,890 +30% Mixed 06 Jul 2026
Carole Ben-Maimon President and CEO, Director $1,521,835 Mixed 26 Jan 2026
Michael Celano Chief Financial Officer $822,140 Mixed 26 Jan 2026
Gopi Shankar Chief Development Officer $291,247 Mixed 26 Jan 2026
Russell Clayton Chief Medical Officer $272,197 Mixed 26 Jan 2026
Frank E. Thomas Director $35,000 +$25,000 +250% Filing P/S 19 May 2026
Jeffrey W. Sherman Director $25,000 +$25,000 +100% Filing P/S 19 May 2026
Peter Barrett Director Mixed 10 May 2022
Daniel Thomas O Director Mixed 12 May 2021
Jonathan S. Leff Director Mixed 19 May 2026
DEERFIELD MANAGEMENT COMPANY, L.P. Director, * Director by Deputization, 10%+ Owner Mixed 19 May 2026
Joseph Truitt Director Mixed 19 May 2026

Recent insider transactions for Larimar Therapeutics, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Thomas Edward Hamilton LRMR Common Stock Purchase 7.52% $166,890 $3.34 50,000 714,798 06 Jul 2026 Direct
Flynn James E LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Through Deerfield Management Company, L.P.
James E. Flynn LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Through Deerfield Management Company, L.P.
Jonathan S. Leff LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Direct
Jeffrey W. Sherman LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Direct
Joseph Truitt LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Direct
Frank E. Thomas LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Direct
Thomas Edward Hamilton LRMR Stock Option (Right to Buy) Award 55,150 55,150 19 May 2026 Direct
James E. Flynn LRMR Common Stock Purchase 47.5% $10,000,000 $5.00 2,000,000 6,207,982 27 Feb 2026 Through Deerfield Partners, L.P.
James E. Flynn LRMR Common Stock Purchase 11.4% $4,159,890 $5.00 831,978 8,153,107 27 Feb 2026 Through Deerfield Healthcare Innovations Fund, L.P.
James E. Flynn LRMR Common Stock Purchase 11.4% $5,420,060 $5.00 1,084,012 10,622,957 27 Feb 2026 Through Deerfield Private Design Fund IV, L.P.
James E. Flynn LRMR Common Stock Purchase 11.4% $5,420,050 $5.00 1,084,010 10,622,928 27 Feb 2026 Through Deerfield Private Design Fund III, L.P.
Thomas Edward Hamilton LRMR Common Stock Purchase 17.7% $500,000 $5.00 100,000 664,798 27 Feb 2026 Direct
Frank E. Thomas LRMR Common Stock Purchase 250% $25,000 $5.00 5,000 7,000 27 Feb 2026 Direct
Jeffrey W. Sherman LRMR Common Stock Purchase $25,000 $5.00 5,000 5,000 27 Feb 2026 Direct
Gopi Shankar LRMR Common Stock Award 50.5% 25,637 76,443 26 Jan 2026 Direct
Gopi Shankar LRMR Stock Option (Right to Buy) Award 153,822 153,822 26 Jan 2026 Direct
Russell Clayton LRMR Common Stock Award 56% 25,637 71,443 26 Jan 2026 Direct
Russell Clayton LRMR Stock Option (Right to Buy) Award 153,822 153,822 26 Jan 2026 Direct
Carole Ben-Maimon LRMR Common Stock Award 37.3% 100,100 368,276 26 Jan 2026 Direct
Carole Ben-Maimon LRMR Stock Option (Right to Buy) Award 600,600 600,600 26 Jan 2026 Direct
Michael Celano LRMR Common Stock Award 21.1% 37,604 215,785 26 Jan 2026 Direct
Michael Celano LRMR Stock Option (Right to Buy) Award 225,622 225,622 26 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .